123 related articles for article (PubMed ID: 20303650)
1. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
4. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
5. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
7. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
8. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
[TBL] [Abstract][Full Text] [Related]
9. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS
Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584
[TBL] [Abstract][Full Text] [Related]
10. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
11. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
12. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.
Gao R; Li L; Shang B; Zhao C; Sheng W; Li D
Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):105-16. PubMed ID: 25615234
[TBL] [Abstract][Full Text] [Related]
13. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
[TBL] [Abstract][Full Text] [Related]
14. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.
Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z
Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754
[TBL] [Abstract][Full Text] [Related]
15. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
[TBL] [Abstract][Full Text] [Related]
16. An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer.
Zhong G; Xu Z; Yang R; Zhang S; Li L; Wu M; Liu H; Zhen Y
J Cancer; 2018; 9(4):674-682. PubMed ID: 29556325
[TBL] [Abstract][Full Text] [Related]
17. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
18. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
19. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array.
Zhong GS; Guo XF; Zhang SH; Zhen YS
Biomed Environ Sci; 2011 Dec; 24(6):602-7. PubMed ID: 22365395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
